| Literature DB >> 25511375 |
Jinyu Chen1, Ho-Jeong Lee2, Xuefeng Wu1, Lei Huo3, Sun-Jin Kim2, Lei Xu1, Yan Wang3, Junqing He2, Lakshmi R Bollu1, Guang Gao1, Fei Su1, James Briggs1, Xiaojing Liu4, Tamar Melman5, John M Asara6, Isaiah J Fidler2, Lewis C Cantley7, Jason W Locasale4, Zhang Weihua8.
Abstract
Breast cancer brain metastasis is resistant to therapy and a particularly poor prognostic feature in patient survival. Altered metabolism is a common feature of cancer cells, but little is known as to what metabolic changes benefit breast cancer brain metastases. We found that brain metastatic breast cancer cells evolved the ability to survive and proliferate independent of glucose due to enhanced gluconeogenesis and oxidations of glutamine and branched chain amino acids, which together sustain the nonoxidative pentose pathway for purine synthesis. Silencing expression of fructose-1,6-bisphosphatases (FBP) in brain metastatic cells reduced their viability and improved the survival of metastasis-bearing immunocompetent hosts. Clinically, we showed that brain metastases from human breast cancer patients expressed higher levels of FBP and glycogen than the corresponding primary tumors. Together, our findings identify a critical metabolic condition required to sustain brain metastasis and suggest that targeting gluconeogenesis may help eradicate this deadly feature in advanced breast cancer patients. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25511375 PMCID: PMC4315743 DOI: 10.1158/0008-5472.CAN-14-2268
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701